Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability by Kliček, Robert et al.
INTRODUCTION
Several important findings recently appear in inflammatory
bowel disease (IBD) and ulcerative colitis (1, 2) in particular,
alterations of the brain-gut interactions ("brain-gut axis") (3)
while stable gastric pentadecapeptide BPC 157 particular
effects on nitric oxide (NO)-system (4), nonsteroidal anti-
inflammatory drugs (NSAIDs)-toxicity, peripheral and central
(5), gastrointestinal tract (6, 7) and wound-healing, and blood
vessels (8), were recently reviewed. Here, BPC 157 was
suggested to be a link between IBD and multiple sclerosis, that
could be also used in practice per-orally (as an anti-ulcer
peptide, stable in human gastric juice) (5-7, 9), and thereby,
being equally effective against the models of both of those
diseases. Thereby, BPC 157 was tested in rats subjected to
cysteamine enema + colon-colon anastomosis colitis (9-11) and
over-dose cuprizone application, a multiple sclerosis suited
toxic experimental model (12).
Interesting from the viewpoint of inflammatory bowel
therapy, endothelium has become one of the major areas of
investigation in gut inflammation (13, 14). Likewise, the cell
layers lining the intestines and blood-brain barrier define treating
the inflammatory bowel disease as well as multiple sclerosis.
Thereby, considering its effects (5-7, 9,15-17), we advocate the
stable gastric pentadecapeptide BPC 157 in both inflammatory
bowel disease and multiple sclerosis therapy. An additional
argument is a direct demonstration of the healing of the severely
injured muscles (15-17) and severely injured nerves (18) and
brain injuries (19-23) not relied on immunomodulation.
At present, natalizumab, a humanized monoclonal antibody
against the cell adhesion molecule a4-integrin, is
advantageously used in the treatment of multiple sclerosis and
Crohn's disease (24). On the other hand, with IBD-current
biologic therapies limited to blocking tumor necrosis factor
alpha some theoretical/practical inconsistencies appear. Mucosal
endothelium is now well recognized to play an active role in the
pathogenesis of both forms of inflammatory bowel disease,
Crohn's disease and ulcerative colitis. Likewise, endothelial cells
are regulating mucosal immune homeostasis, acting as
"gatekeepers", controlling leukocyte accumulation in the
interstitial compartment; the process mediated by leukocyte-
endothelial adhesion molecules. However, with IBD-current
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Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and
thereby, shown to equally counteract the models of both of those diseases. For colitis, cysteamine (400 mg/kg intrarectally
(1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used. BPC 157 (10 µg/kg, 10 ng/kg) was
applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before
sacrifice) or per-orally in drinking water (0.16 µg/ml/12 ml/day till the sacrifice) while controls simultaneously received
an equivolume of saline (5 ml/kg) intraperitoneally or drinking water only (12 ml/day). A multiple sclerosis suited toxic
rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg
intragastrically/day) was combined with BPC 157 (in drinking water 0.16 µg or 0.16 ng/ml/12 ml/day/rat + 10 µg or 10
ng/kg intragastrically/day) till the sacrifice at day 4. In general, the controls could not heal cysteamine colitis and colon-
colon anastomosis. BPC 157 induced an efficient healing of both at the same time. Likewise, cuprizone-controls clearly
exhibited an exaggerated and accelerated damaging process; nerve damage appeared in various brain areas, with most
prominent damage in corpus callosum, laterodorsal thalamus, nucleus reunions, anterior horn motor neurons. BPC 157-
cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most
affected. Consistently, BPC 157 counteracted cerebellar ataxia and impaired forelimb function. Thereby, this experimental
evidence advocates BPC 157 in both inflammatory bowel disease and multiple sclerosis therapy.
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biologic therapies, all these mean some patients primary non-
responders, experience a loss of response, intolerance or side
effects, defining the urgent unmet need for novel treatments (13,
14). Likewise, also important for multiple sclerosis therapy,
natalizumab also carries a specific risk of progressive multifocal
leucoencephalopathy and reactivation of JC virus infection (24).
As an alternative, previously, there was an established BPC
157-NO system interaction (4, 8, 25-27) as well as a particular
potential in angiogenesis (28-30) especially evident in the
advanced healing process of the various tissues (25, 31-38)
including those that may be almost avascular (i.e., tendon,
ligament) (37). Thereby, likely, fewer lesions in BPC 157-
therapy, is possibly a particular effect of pentadecapeptide BPC
157 itself on the endothelium integrity (long-ago demonstrated
(39)) since acting as a novel mediator of Robert's cytoprotection
in stomach that essentially maintains endothelium integrity (5,
9). In support, the counteracting effect of BPC 157 on L-NAME
was parallel with its endothelium protection and mucosal
integrity maintenance (33); in rats with abdominal aorta
anastomosis BPC 157 both prevents thrombotic clot formation
and destroys already formed thrombosis (40) and also, after
amputation, BPC 157 reduces bleeding time and
thrombocytopenia after heparin, warfarin or aspirin
administration (41). Likewise, when BPC 157 rescued
doxorubicine-cardiac failure (33), supporting were the effects of
BPC 157 medication on serum endothelin values: with a
prevented increase along with prevented heart failure
development and reversal of the increased values toward normal
levels along with cardiac failure reversal (33).
This particular effect on endothelium integrity (termed also
"wound healing therapy") (5-7, 9) may explain that initially for
inflammatory bowel research, throughout a short term period
and long term therapy, various intestinal lesions models were
cured. Most improvement was achieved by BPC 157 regimens
(42, 43) per-orally, parenterally and locally, even when
complicated with relapse, poor healing of the fistulas, unhealed
intestinal anastomosis (10, 11, 35, 42, 43) massive intestinal
resection leading to short bowel (43) and functional incapability
of the post-anastomotic remained intestine. Also, reversed was
increased number of inflammatory cells (38, 44-46) and raised
leukotriene B4 (LTB4), thromboxane B2 (TXB2), and
myeloperoxidase (MPO) in the serum and inflamed tissues (47-
49). And finally, BPC 157 increases macrophages activity (50).
This marked potential effect (5-7, 9) is interesting since BPC 157
is originally an anti-ulcer peptide (GEPPPGKPADDAGLV,
M.W. 1419), stable in human gastric juice, accordingly
investigated in trials for inflammatory bowel disease, wound
treatment, with no toxicity reported, where LD1 could be not
achieved, effective alone without carrier (5-7, 9). Moreover,
nonsteroidal anti-inflammatory drugs (NSAIDs), prototypic
inhibitors of cyclooxygenase (COX) activity and PGE2
production, can trigger or worsen the disease (51, 52). Contrary,
BPC 157 consistently counteracts various lesions that may be
produced by various NSAIDs (20-22, 53), and thereby suggested
as an antidote for NSAIDs-toxicity (5). In these terms, the
effects of BPC 157 on adjuvant arthritis a suited model of
rheumatic arthritis, both prevention and rescue of the already
established advanced failure (53), may be taken as a purposeful
extension.
It particularly and consistently interacts with the NO-system,
in various models and different species (4, 8, 25-27). Besides, it
stimulated expression of early growth response 1 (egr-1) gene
responsible for cytokine and growth factor generation and early
extracellular matrix (collagen) formation (but also its repressor
nerve growth factor 1-A binding protein-2 (nab2)) (44).
Therefore, considering significance of both NO-system and
egr-1 gene-systems for inflammatory bowel disease (54) as well
as for multiple sclerosis (55-57), these may be important also
when confronted with severe complications of advanced and
poorly controlled IBD as well as multiple sclerosis.
No therapy currently exists to repair demyelinated lesions in
multiple sclerosis (58). However, besides arguments mentioned
before, BPC 157 also provided direct demonstration of the
healing of the severely injured muscles (15-17) and severely
injured nerves (18, 59) and brain injuries (19-23) not relied on
immunomodulation. Whether this approach may be suited to
counteract these disabilities in multiple sclerosis patients,
remains to be further determined. It should be, however, noted
that there is a general lack of the studies that would demonstrate,
for instance, the healing effect of disease-modifying drugs
(DMDs) on the severely injured muscles and severely injured
nerves. Unfortunately, several treatments, though successful in
pre-clinical experimental autoimmune encephalitis trials, were
either less effective in patients, worsened disease or caused
unexpected, severe adverse events, as reviewed (60).
Therefore, the problem that the agents successful in pre-
clinical experimental autoimmune encephalitis trials, were either
less effective in patients, worsened disease or caused
unexpected, severe adverse events (60), may be at least partly
solved with the more suited cuprizone model that reflects a toxic
experimental model (12). Cuprizone-induced demyelination in
animals is accepted for studying multiple sclerosis-related
lesions and is characterized by degeneration of oligodendrocytes
more than by a direct attack on the myelin sheet (12).
As emphasized, currently, only injectable drugs are available
for the treatment of multiple sclerosis (61). Therefore emerging
oral therapies for multiple sclerosis are an especially attractive
alternative to current DMDs (61). Thus, to highlight possible
application of pentadecapeptide BPC 157 in both IBD and
multiple sclerosis patients, this study shows BPC 157's potential
to counteract the consequences of the cuprizone application,
used in an extremely high regimen that highly exceeds those
commonly applied (62). In cuprizone-rats, BPC 157 was given
per-orally in the same regimen that may rescue rats with severe
ulcerative colitis and colon-colon anastomosis.
MATERIALS AND METHODS
Animals
Male Wistar Albino rats (200–250 g) randomly assigned, 10
rats per each experimental group, were used in all experiments.
They were fed with a standard rodent chow, ad libitum. All
experiments were approved by the Local Ethics Committee.
Drugs and materials
Pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W.
1419), (Diagen, Ljubljana, Slovenia) dissolved in saline, was
used in all experiments. The peptide BPC 157 is part of the
sequence of human gastric juice protein BPC, and is freely
soluble in water at pH 7.0 and saline. It was prepared as
described previously with 99% high pressure liquid
chromatography (HPLC) purity, expressing 1-des-Gly peptide as
an impurity, cysteamine (Sigma,USA), and cuprisone (Sigma,
USA) were accordingly used (5-7, 9, 62).
Colon-colon anastomosis complicated by the cysteamine-
induced colitis
Under deep anesthesia the cysteamine (400 mg/kg) was
applied through enema (1 ml/rat) at 8 cm proximal to the anus
(as described before) (5-7, 9) and 10 minutes thereafter, the
598
colon-colon anastomosis was created 5 cm proximal to anus.
Single-layer colon-colon anastomosis was performed with 7–0
polypropylene (Prolene; Ethicon, Hamburg, Germany)
interrupted sutures; the abdominal incision was closed with 3–0
silk sutures. The sacrifice was at day 3, 5, 7, and 14.
Medication
BPC 157 (10 µg/kg, 10 ng/kg) was applied either
intraperitoneally once time daily (first application immediately
after surgery, last at 24 hours before sacrifice) or per-orally in
drinking water (0.16 µg/ml/12 ml/day till the sacrifice) while
controls simultaneously received an equivolume of saline (5
ml/kg) intraperitoneally or drinking water only (12 ml/day).
Anastomosis and cysteamine colitis healing assessment
was performed at day 3, 5, 7, and 14 as described before (5-7,
9-11, 42, 43), the stool formation (scored 1 or 2, unformed or
formed), weight loss (D, g, initial weight-post-surgery weight)
and survival (number of survived and dead rats) were assessed
initial as well. Briefly, as described (42), passage obstruction
scored 0–3 (according to the loop diameters ratio close to
anastomosis, loop diameters orally/loop diameters aborally = 1
passage is normal (score 0), between 1 and 1.33 is the sign of
mild obstruction (score 1), between 1.33 and 1.66 is moderate
obstruction (score 2), and more than 1.66 is severe obstruction
(score 3)); adhesion presentation scored 0–7 (0, no adhesion; 1,
thin adhesions covering less than one half of anastomosis; 2,
more prominent adhesions with more than half of anastomosis;
3, exaggerated adhesions with whole anastomosis; 4, the
mesenterial part of bowel also included; 5 neighboring loop
also included; 6, many neighboring loops included; 7,
neighboring loops, stomach, liver "packed"), cysteamine colitis
the lesions areas were assessed by naive observers by a
morphometrical analysis system (using a PC based program
SFORM, VAMS, Zagreb, Croatia). Representative tissue
sections were processed for further histologic analysis as
described before (5-7, 9-11, 42, 43).
Biomechanics
Anastomosis dehiscence was biomechanically assessed in
separate groups of animals, under deep anesthesia as described
before (35, 42, 43). We studied the volume (ml) to the leak
induction. Volume was infused through a syringeperfusion pump
system (Argus 600, Argus Medical A6, Heimberg, Switzerland)
(1 ml/10 s) in 10 cm colon segment with colitis and with
anastomosis between 5 cm orally and 5 cm aborally, and
corresponding 10 cm colon segment with colitis but without
anastomosis.
Microscopy
The tissue specimens were immediately fixed in buffered
formalin (pH 7.4), for 24 hours, dehydrated, and embedded in
paraffin wax. The samples were stained with hematoxylin-
eosin. Briefly, as described before (42), necrosis and
granulation tissue formation were scored as follows: none (0);
presentation less than 20% of the anastomosis area (1);
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Parameter description Score Scoring description 
0 Hindlimbs are consistently splayed outward, away from the abdomen 
1 One hindlimb is retracted toward the abdomen for more than 50% of the time suspended
2 Both hindlimbs are partially retracted toward the abdomen for more than 50% of the time suspended
Hindlimb clasping:   
Grasping the tail near its base 
and lifting the rat clear of all 
surrounding objects, 
observing the hindlimb 
position for 10 seconds  
3 Hindlimbs are entirely retracted and touching the abdomen for more than 50% of the time suspended
0 Rat walks along the ledge without losing its balance, and lowers itself back into the cage gracefully, using its paws. 
1 Rat loses its footing while walking along the ledge, but otherwise appears coordinated.
2
Rat does not effectively use its hind legs, rear body reclines 
and rat lands on its head rather than its paws when
descending into the cage. Body tremor can be observed. 
The ledge test:  
Rat is placed on the cage`s 
ledge and it`s walking on the 
ledge and lowering in the cage 
is observed and scored 
3
Rat falls off the ledge, or nearly so, while walking or 
attempting to lower itself, or shakes and refuses to move at 
all despite encouragement 
0 
Rat moves normally, with its body weight supported on all 
limbs, with its abdomen not touching the ground, and with 
both hindlimbs participating evenly. 
1 Rat shows a tremor or appears to limp while walking, feet point away from the body during locomotion ("duck feet").
2
Rat shows a severe tremor, severe limp, "duck feet", 
forelimb treading, dyskinesia is present less than 50% of the 
time.
Gait: 
Rat is observed and scored 
while walking on the flat 
surface  
3
Rat has difficulty in moving forward and drags its abdomen 
along with the ground, akinesia or dyskinesia are present 
more than 50 % of the time. 
0 Rat is able to easily straighten its spine as it walks, and does not have persistent kyphosis. 
1 Rat exhibits mild kyphosis but is able to straighten its spine.
2 Rat is unable to straighten its spine completely and maintains persistent but mild kyphosis.
Kyphosis:  
Rat’s spine is observed and 
scored while rat is walking on 
the flat surface. 
3 Rat maintains pronounced kyphosis as it walks or while it sits.
Table 1. Impaired forelimb function scoring (see 63, 64).
presentation between 20% and 60% of the anastomosis area (2);
presentation more than 60% of the anastomosis area (3), and
edema, inflammatory cells, granulocytes, macrophages,
fibroblasts were scored, scored on a four-point scale 0-3 (not;
little; much; very much), and percentage of epithelization in
anastomotic area and anastomotic area (mm) without new
smooth muscle strands were assessed as before (42). Mallory-
Gomory (reticulin, collagen), or immunohistochemically for
desmin (Dako, Glostrup, Denmark) (newly formed muscle) and
were examined in a blinded fashion. For the morphometrical
analysis special software programs SFORM and ISSA
(VAMSTEC, Zagreb, Croatia) were used. Five high power
fields were randomly selected for the analysis.
Cuprizone-brain damage and motoric disability
Cuprizone 2.5% of diet regimen was combined with BPC
157 in drinking water 10 µg/kg or 10 ng/kg, 0.16 µg/ml/12
ml/day or 0.16 ng/ml/12 ml/day till the sacrifice after four days,
with the additional applications once daily, last application at 24
hours before sacrifice: cuprizone 1 g/kg intragastrically while
BPC 157 was given 10 µg/kg or 10 ng/kg intragastrically,
controls received intragastrically an equivolume (5 ml/kg) of
saline.
Behavioral assessment: cerebellar ataxia scoring
A protocol for the rapid and sensitive quantification of
disease in rodent models of cerebellar ataxia (63) is described in
Table 1.
Rats were assessed for fine motoric impairment with
modified Irvine, Beatties and Bresnahan forelimb scale (IBB
scale) that can detect recovery of both proximal and distal
forelimb function including digit movements during a naturally
occurring behavior that does not require extensive training or
deprivation to enhance motivation (64). While IBB scale is more
detailed and adjusted for fine motoric impairment due to cervical
spinal cord injury, our modified and simpler scale reflects
impairment due to cuprizone induced central nervous system
injury. Rats were tested in 30 cm tall glass cylinder. The animals
were first adapted to testing environment after a shortened pellet
(1×0.3 cm), their usual diet, was administered in the cylinder.
Rats were recorded and afterwards assessed (slow-down video)
for forelimb function impairment. The overall score of forelimb
function impairment was obtained from 6 parameters. The
highest score of 10 points reflects the greatest impairment, while
the lowest score of 0 points represents normal forelimb function.
The modified IBB scale (64) is presented in Table 2.
Accordingly with previous studies (63, 64), animal
responsiveness to forceps stimuli is tested with blunt-nosed
thumb forceps with serrated tips for increased grip. Animals are
tested in glass cylinder, where they adapt for 10 minutes prior to
assessment. Experimenter lowers the forceps in cylinder in front
of the rat, stimulates it`s whiskers and slightly touches it`s chest
while recording and scoring rat`s reaction to stimuli. Healthy
controls rear, raise their both forelimbs and grasp the forceps
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Parameter Score Description 
0 Normal pellet adjustment, subtle movements without a loss of contact between the forepaws and the pellet during eating. 
1 
Exaggerated pellet adjustment movements by the shoulder and/or 
elbow and/or wrist of the forelimbs that produce a complete loss of 
contact between forepaws and the cereal. 
Pellet adjustment  
2 Unability of pellet adjustement, no adjustment movement of one or both forelimbs 
0 Partially flexed adaptable - The digits are partially flexed and conform to the shape of the pellet Predominant forepaw position  
1 Extended non-adaptable - The digits are extended with an angle of >160° and do not conform to the shape of the held pellet. 
0 No support with the volar surface of the forepaw during eating (less than 5% of the time). 
1 Support of the pellet with the volar surface of the forepaw does occur during eating but not always (less than 95% of the time). 
Contact volar 
support  
2 No support with the volar surface of one or both forepaws during eating (less than 5% of the time). 
0 Normal grasping method during more than 90% of the time of eating 
1 Normal grasping method during 60 to 90% of the time of eating 
2 Normal grasping method during 10 to 60% of the time of eating 
Grasping method  
3 Normal grasping method less than 10 % of the time during eating 
0 Abilty to grasp pellet Ability of pellet 
grasping  1 Inabilty to grasp pellet 
0 Ability to raise the pellet above the cylinder bottom Pellet raising  
1 Inability to raise the pellet above the cylinder bottom 
Table 2. The modified IBB scale for assessment of forelimb function impairment (see 66, 67).
Parameters assessed  Score 
Rearing in a response to forceps stimuli 0 
Raising both forepaws and touching forceps with 
volar surface   0 
Raising only left forepaw and touching forceps 
with volar surface 1 
Raising both forepaws in a direction of forceps 
but without touching them with volar surface 1 
Raising only left forepaw in a direction of forceps
but without touching them with volar surface 2 
Losing body balance after rearing 3 
Unresponsiveness at the beginning of testing 4 
Complete unresponsiveness 5 
Table 3. Animal responsiveness to forceps stimuli (see 63, 64).
nose defensively. Animals affected with cuprizone toxicity react
only with one or no forelimb and have difficulty with
maintaining body balance while rearing. Scoring system is
presented in Table 3.
Behavioral assessment: microscopy
Brains were fixed in 4% paraformaldehyde (PFA) for two
days. The brain was cut into consecutive coronal sections. Brain
slabs were dehydrated in graded ethanol and embedded in
paraffin. Paraffin blocks were cut into 5 and 3- µm slices.
Paraffin slices cut into 5-µm were deparaffinated in xylene,
rehydrated in graded ethanol and stained with hematoxylin and
eosin. Paraffin slices cut into 3-µm were deparaffinated in
xylene, rehydrated untill 70% ethanol and stain in 0.1% cresyl
violet solution for Nissl staining method. The intensity and
distribution of brain lesions (balloonized or red neurons), were
described and evaluated semi-quantitatively as follows (19-23):
0–5% balloonized or red neurons (1), 6–10% balloonized or red
neurons (2), 11–15% balloonized or red neurons (3), 16–20%
balloonized or red neurons (4), 21–30% balloonized or red
neurons (5), >31% balloonized or red neurons (6). The degree of
neuronal loss in hippocampal regions CA1 were described and
evaluated semi-quantitatively as follows: 0–10% (1), 11–20%
(2) and >21% (3). For motor neuron count, spinal cords from
anesthetized rats were collected and post-fixed for 12 hours in
4% PFA. Paraffin-embedded spinal cords were serially sectioned
at 5 µm steps, mounted on slides, and processed for Nissl
staining. Images of ten contiguous sections were analyzed.
Motor neurons were identified as cells positive for Nissl
staining, with clear nucleus and nucleolus. Counting was
performed in a blinded fashion. The intensity of red neurons
were described and evaluated semi-quantitatively as follows:
0–25% (1), 26–50% (2) and >50% (3).
Statistical analysis
Statistical analysis was performed using parametric two-way
mixed model ANOVA (one factor is repeated-measures) and
Student Newman-Keuls test to compare the difference between
groups. Fisher's exact probability test was used to assess the
number of dead and surviving rats. A P value of 0.05 or less was
considered statistically significant.
RESULTS
Here, to evidence a link between inflammatory bowel
disease and multiple sclerosis that may be useful in practice,
BPC 157 was used per-orally in rats subjected to cysteamine
enema + colon-colon anastomosis colitis (9-11) and over-dose
cuprizone application, a multiple sclerosis suited toxic
experimental model (12). BPC 157 was used in the same regular
regimens (10 µg or 10 ng/kg, per-orally/intragastrically), shown
to be effective in all BPC 157 studies (5, 9). Since cuprizone
regimen was several times higher than those regularly used in
cuprizone studies (62) we used simple tests (Tables 1-3) to
determine animal responsiveness and impairment. The
anastomosis and the ulcerative colitis at the same time were
assessed grossly, biomechanically, clinically and
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Number of survived/dead rats 
throughout days after cysteamine 
enema + colon-colon anastomosis Regimens Medication 
Day 3 Day 5 Day 7 Day 14 
Saline 5 ml/kg 10/5 7/8 6/9 4/11 
BPC 157 10 µg/kg 15/0* 15/0* 15/0* 15/0* Once daily, intraperitoneally 
BPC 157 10 ng/kg 15/0* 15/0* 12/3* 11/4* 
Drinking water 10/5 7/8 6/9 4/11 Per-orally in drinking 
water (12ml/day till 
the sacrifice) 
BPC 157  
(10 µg/kg, 0.16 µg/ml) 15/0* 15/0* 15/0* 13/2* 
Table 4. Mortality rate in rats that received cysteamine enema, and then colon-colon anastomosis, and thereby, poor anastomosis
healing along with prominent ulcerative colitis. * P<0.05, vs. control.
Cerebellar ataxia scoring (0–3, Min/Med/Max). Impaired forelimb function 
scoring in rats that received cuprizone diet, and then cuprizone intragastrical 
applications 
Therapy (/kg): 
(i) in drinking water  
(12 ml/day) till the sacrifice,  
nothing or BPC 157  
(10 µg, 10 ng)  
(0.16 µg, 0.16 ng/ml/)  
+(ii) saline or BPC 157  
(10 µg, 10 ng), 
intragastrically,  
after cuprizone instillations 
Hindlimb clasping:  
Grasping the tail 
near its base and 
lifting the rat clear of 
all surrounding 
objects, observing 
the hindlimb 
position for 10 
seconds 
The ledge test:  
Rat is placed on 
the cage`s ledge 
and it`s walking on 
the ledge and 
lowering in the 
cage is observed 
and scored 
Gait: 
Rat is observed 
and scored 
while walking 
on the flat 
surface. 
Kyphosis: 
Rat`spine is 
observed and 
scored while 
rat is walking 
on the flat 
surface 
Saline 5 ml 2/2/3 1/1/1 2/2/3 3/3/3 
BPC 157 10 µg 0/0/0* 0/0/0* 0/0/0* 0/0/0* 
Noxious procedure for 4 days: 
(i)cuprizone 2.5% diet +  
(ii) cuprizone 1 g/kg 
intragastrically  
once daily
BPC 157 10 ng 1/1/1* 0/0/1* 0/1/2* 0/1/1* 
Table 5. Cerebellar ataxia scoring (0–3, Min/Med/Max). Impaired forelimb function scoring in rats that received cuprizone diet, and
then cuprizone intragastrical applications, and thereby, cuprizone toxicity manifestations. BPC 157 (10 µg/kg, 10 ng/kg) was applied
either per-orally in drinking water (0.16 µg/ml/12 ml/day; 0.16 ng/ml/12 ml/day till the sacrifice) and intragastrically after cuprizone
instilations, while controls received simultaneously drinking water only (12 ml/day) as well as an equivolume of saline (5 ml/kg)
intragastrically after cuprizone instillations. * P<0.05, at least, vs. control.
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Fig. 1. Cysteamine enema, and then colon-colon
anastomosis, and thereby, poor anastomosis
healing along with prominent ulcerative colitis.
Counteraction by various BPC 157 regimens.
Presentation of colitis lesions, damaged area, mm2,
and colitis bursing pressure assessed as the volume
(ml) of infunded water before leaking appearance
in colitis-intestine. BPC 157 (10 µg/kg, 10 ng/kg)
was applied either intraperitoneally, once time
daily (first application immediately after surgery,
last at 24 hours before sacrifice) or per-orally in
drinking water (0.16 µg/ml/12 ml/day till the
sacrifice) while controls simultaneously received
an equivolume of saline (5 ml/kg) intraperitoneally
or drinking water only (12 ml/rat/day). *P<0.05, at
least, vs. control.
Fig. 2. Cysteamine enema, and then colon-colon
anastomosis, and thereby, poor anastomosis
healing along with prominent ulcerative colitis.
Counteraction by various BPC 157 regimens.
Presentation of non-formed and formed stool
(scored 1–2), and weight loss (as D, g (initial
weight-post-surgery weight)). BPC 157 (10 µg/kg,
10 ng/kg) was applied either intraperitoneally once
time daily (first application immediately after
surgery, last at 24 hours before sacrifice) or per-
orally in drinking water (0.16 µg/ml/12 ml/day till
the sacrifice) presented with mostly formed stool
and pre-surgery weight achieved. Controls
simultaneously received an equivolume of saline (5
ml/kg) intraperitoneally or drinking water only (12
ml/rat/day), and presented with non-formed stool
and sustained weight loss. * P<0.05, at least, vs.
control.
microscopically (Table 4, Figs. 1-7). As an illustration, the BPC
157 animals exhibited less colitis lesions and advanced
anastomosis healing and functioned much better and mostly
achieved pre-operative weigh. They exhibited the higher
survival rate (Table 4), formed feces 3 days following surgery
(Fig. 2) and the absence of passage impairment (Fig. 3).
Likewise, cuprisone + BPC 157 rats functioned markedly better
(Tables 5-7, Fig. 8) and exhibited less nerve damage in various
brain areas (Table 8, Fig. 9).
Cysteamine colitis
In general, the controls could not heal cysteamine colitis and
colon-colon anastomosis. Like in previous studies (10, 11),
either of BPC 157 regimens exhibited all colitis lesions
consistently attenuated, macroscopically (Fig. 1), clinically
(Figs. 2, 3) and microscopically (Figs. 4-6). As described before,
in rats treated with BPC 157 we substantiated a strong benefit
(i.e., less necrosis, increased epithelization, new strands of
smooth muscle formed, and more granulation, less number of
inflammatory cells) (Figs. 4-7). And thereby, their biomechanic
assessment demonstrated markedly higher intestine strength
before leaking (Figs. 1, 3) along with a general improvement
(i.e., formed stool, no passage obstruction, less adhesions
presentation, and maintained weight) (Figs. 2, 7). Thereby,
beneficial course was not hampered by the close anastomosis in
rats that received BPC 157.
Colon-colon anastomosis
Specifically, the anastomosis in controls healed poorly (Figs.
3-7), grossly, clinically, microscopically, and in particular,
biomechanically, and they could sustain without leaking only a
very small volume (Fig. 3). Likewise, their adjacent colon
relatively far from anastomosis, but with colitis, could sustain
only a very small amount of the infunded water (Fig. 1).
Contrary, the colon-colon anastomosis and adjacent colon in
animals treated with the pentadecapeptide BPC 157 sustained
markedly higher infunded volume without leaking. From the 7th
postoperative day, they presented values comparative to those of
healthy animals (Figs. 1, 3).
Likewise, unlike controls presented with huge adhesions,
and prominent passage impairment, BPC 157 rats exhibited
markedly improved post-operative course, markedly less
adhesions and no passage obstruction (Figs. 3-7).
Cuprizone-brain damage and motoric disability
The used cuprizone regimen, several times higher than
those regularly used in cuprizone studies (62), rapidly induced
marked functional disability along with severely affected
various brain areas. For instance, as an illustration, control
animals affected with cuprizone toxicity spare right forelimb,
and thereby react only with one or no forelimb and have
difficulty with maintaining body balance while rearing.
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Fig. 3. Cysteamine enema, and then colon-colon
anastomosis, and thereby, poor anastomosis
healing along with prominent ulcerative colitis.
Counteraction by various BPC 157 regimens.
Presentation of anastomosis bursting pressure
(assessed as the volume (ml) of infunded water
before leaking appearance in anastomosis), passage
obstruction (scored 0–3), and extent of adhesions
formation (scored 0–7). BPC 157 (10 µg/kg, 10
ng/kg) was applied either intraperitoneally once
time daily (first application immediately after
surgery, last at 24 hours before sacrifice) or per-
orally in drinking water (0.16 µg/ml/12 ml/day till
the sacrifice) presented with small extent of
adhesions, increased anastomosis bursting pressure
and no passage obstruction. Controls
simultaneously received an equivolume of saline (5
ml/kg) intraperitoneally or drinking water only (12
ml/rat/day), and presented with significant
adhesions, small bursting pressure and significant
passage bstruction. * P<0.05, at least, vs. control.
Contrary, BPC 157 rats do not spare right forelimb, and they
react simultaneously with both forelimbs, and grasp the
forceps, and maintain body balance while rearing (Tables 5-7,
Fig. 8).
Nerve damage appeared in various brain areas, with most
prominent damage in corpus callosum, laterodorsal thalamus,
nucleus reunions, anterior horn motor neurons. Thereby,
considering BPC 157 therapy, it is important to indicate
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Fig. 4. Anastomotic gap presentation
microscopically assessed in in rats that received
cysteamine enema, and then colon-colon
anastomosis, and thereby, poor anastomosis
healing along with prominent ulcerative colitis if
not rescued by various BPC 157 regimens.
Necrosis (scored 0–3), percentage of gap with
surface epithelium regeneration present, gap
without new strands of smooth muscle. BPC 157
(10 µg/kg, 10 ng/kg) was applied either
intraperitoneally once time daily (first application
immediately after surgery, last at 24 hours before
sacrifice) or per-orally in drinking water (0.16
µg/ml/12 ml/day till the sacrifice) while controls
simultaneously received an equivolume of saline (5
ml/kg) intraperitoneally or drinking water only (12
ml/rat/day). * P<0.05, at least, vs. control.
Modified Irvine, Beatties and Bresnahan forelimb scale (IBB scale, scored 0–2, 0–3, 
0–1)) for recovery of both proximal and distal forelimb function including digit 
movements during a naturally occurring behavior in rats that received cuprizone diet, 
and then cuprizone intragastrical applications.  
Therapy (/kg):  
(i) in drinking water  
(12 ml/day)  
till the sacrifice,  
nothing or BPC 157  
(10 µg, 10 ng),  
(0.16 µg, 0.16 ng/ml/)  +  
(ii) saline or  
BPC 157 (10 µg, 10 ng), 
intragastrically,  
after cuprizone 
instillations 
Pellet 
adjustment 
Predominant 
forepaw 
position 
Contact volar 
support 
Grasping 
method  
Ability  
of pellet 
grasping 
Pellet raising 
Saline 5 ml 2/2/3 1/1/1 2/2/3 2/2/2 1/1/1 1/1/1 
BPC 157 10 µg 0/0/0* 0/0/0* 0/0/0* 0/0/0* 0/0/0* 0/0/0* 
Noxious procedure for 4 days: 
(i)
cuprizone 2.5% diet +  
(ii)
cuprizone 1 g/kg, 
intragastrically,  
once daily
BPC 157 10 ng 1/1/1* 0/0/1* 0/1/1* 0/1/1* 0/0/0* 0/0/0* 
Table 6. Modified Irvine, Beatties and Bresnahan forelimb scale (IBB scale, scored 0–2, 0–3, 0–1) (63, 64) for assessment of forelimb
function impairment in rats that received cuprizone diet, and then cuprizone intragastrical applications, and thereby, cuprizone toxicity
manifestations. BPC 157 (10 µg/kg, 10 ng/kg) was applied either per-orally in drinking water (0.16 µg/ml/12 ml/day; 0.16 ng/ml/12
ml/day till the sacrifice) and intragastrically after cuprizone instilations, while controls received simultaneously drinking water only
(12 ml/day) as well as an equivolume of saline (5 ml/kg) intragastrically after cuprizone instillations. * P<0.05, at least, vs. control.
consistently less nerve damage appeared in all damaged areas in
all cuprizone + BPC 157 rats. However, the most important
evidence is consistent beneficial effect of BPC 157 also in those
areas that were most affected (Table 8, Fig. 9).
DISCUSSION
BPC 157 was suggested to be a link between inflammatory
bowel disease and multiple sclerosis, that could be also used in
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Fig. 5. Anastomotic gap presentation
microscopically assessed in in rats that received
cysteamine enema, and then colon-colon
anastomosis, and thereby, poor anastomosis
healing along with prominent ulcerative colitis if
not rescued by various BPC 157 regimens. Edema,
granulation tissue, inflammatory cells scored 0–3.
BPC 157 (10 µg/kg, 10 ng/kg) was applied either
intraperitoneally once time daily (first application
immediately after surgery, last at 24 hours before
sacrifice) or per-orally in drinking water (0.16
µg/ml/12 ml/day till the sacrifice) while controls
simultaneously received an equivolume of saline (5
ml/kg) intraperitoneally or drinking water only (12
ml/rat/day). *P<0.05, at least, vs. control.
Therapy (/kg): 
(i) in drinking water (12 ml/day) till the sacrifice, nothing or BPC 157 (10 
µg, 10 ng, 0.16 µg, 0.16 ng/ml/) + (ii) saline or BPC 157 (10 µg, 10 ng), 
intragastrically, after cuprizone instillations  
Noxious procedure for 
4 days:  
(i) cuprizone 2.5% diet 
+  
(ii) cuprizone 1 g/kg, 
intragastrically,  
once daily
Control  
(drinking water (12 
ml/day)  
+ saline 5 ml, 
intragastrically)  
BPC 157 (10 µg, 0.16 
µg/ml,  
in drinking water)  
+ (10 µg, 
intragastrically)  
BPC 157 (10 ng, 0.16 
ng /ml,  
in drinking water)  
+ (10 ng, 
intragastrically) 
Responsiveness to 
forceps stimuli
4/4/5 0/0/0* 0/0/0* 
Table 7. Responsiveness to forceps stimuli in rats (64) (scored 0–5, min/med/max) that received cuprizone diet, and then cuprizone
intragastrical applications, and thereby, cuprizone toxicity manifestations. BPC 157 (10 µg/kg, 10 ng/kg) was applied either per-orally
in drinking water (0.16 µg/ml/12 ml/day; 0.16 ng/ml/12 ml/day till the sacrifice) and intragastrically after cuprizone instilations, while
controls received simultaneously drinking water only (12 ml/day) as well as an equivolume of saline (5 ml/kg) intragastrically after
cuprizone instillations. * P<0.05, at least, vs. control.
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Fig. 6. Anastomotic gap presentation
microscopically assessed in rats that received
cysteamine enema, and then colon-colon
anastomosis, and thereby, poor anastomosis
healing along with prominent ulcerative colitis if
not rescued by various BPC 157 regimens.
Granulocytes, macrophages, fibroblasts scored
0–3. BPC 157 (10 µg/kg, 10 ng/kg) was applied
either intraperitoneally once time daily (first
application immediately after surgery, last at 24
hours before sacrifice) or per-orally in drinking
water (0.16 µg/ml/12 ml/day till the sacrifice)
while controls simultaneously received an
equivolume of saline (5 ml/kg) intraperitoneally or
drinking water only (12 ml/rat/day). *P<0.05, at
least, vs. control.
Therapy (/kg):  
(i) in drinking water (12 ml/day) till the sacrifice, nothing or BPC 
157 (10 µg, 10 ng,0.16 µg, 0.16 ng/ml/) + (ii) saline or BPC 157 
(10 µg, 10 ng), intragastrically, after cuprizone instillations  
Noxious procedure for 
4 days:  
(i) cuprizone 2.5% diet 
+   
(ii) cuprizone 1 g/kg, 
intragastrically,  
once daily
Control  
(drinking water (12 
ml/day) 
+ saline 5 ml, 
intragastrically) 
BPC 157 (10 µg, 
0.16 µg /ml, in 
drinking water) + 
(10 µg, 
intragastrically)
BPC 157 (10 ng, 
0.16 ng /ml, in 
drinking water) + 
(10 ng, 
intragastrically) 
Cingulate 
cortex 2/2/3 1/1/1* 1/1/2*
Temporal 
neocortex 3/3/3 2/2/2* 2/3/3
Corpus calosum 5/5/5 2/2/2* 2/2/2*
Nucleus 
reuniens 5/5/5 2/2/2* 3/3/3*
Laterodorsal 
thalamic nuclei 5/5/5 3/3/3* 3/3/4*
Hippocampus, CA1 2/3/3 1/1/1* 1/1/2*
Motor neurons 6/6/6 1/1/1* 2/2/2*
Table 8. Brain and spinal cord lesions (scored 0–5, or 1–3, Min/Med/Max) in rats that received cuprizone diet, and then cuprizone
intragastrical applications, and thereby, cuprizone toxicity manifestations. BPC 157 (10 µg/kg, 10 ng/kg) was applied either per-orally
in drinking water (0.16 µg/ml/12 ml/day; 0.16 ng/ml/12 ml/day till the sacrifice) and intragastrically after cuprizone instilations, while
controls received simultaneously drinking water only (12 ml/day) as well as an equivolume of saline (5 ml/kg) intragastrically after
cuprizone instillations. *P<0.05, at least, vs. control.
practice per-orally (as an anti-ulcer peptide, stable in human
gastric juice) (5-7, 9), and thereby, being equally effective
against the models of both of those diseases. Thereby, this study
focused on BPC 157 effectiveness as a comparative link in both
diseases, as far it may be indicated by the two models, cuprizone
and cysteamine enema and then colon-colon anastomosis that
fairly mimic corresponding human conditions, multiple sclerosis
(12) and inflammatory bowel disease, colitis and colon-colon
anastomosis (9). Considering the endothelium integrity as a
common denominator for both inflammatory bowel disease and
multiple sclerosis, due to its particular effect of on endothelium
integrity shown in advanced healing effect in the various tissues;
muscle (15-17), nerve (18, 59) and brain injuries (19-23) not
relied on immunomodulation, and especially in GI tract for
inflammatory bowel research, i.e., relapse (10, 11), poor healing
of the fistulas (35), unhealed intestinal anastomosis (42, 43),
massive intestinal resection leading to short bowel (43), and
functional incapability of the post-anastomotic remained
intestine (43), and, along with these, particularly for multiple
sclerosis, direct demonstration of the healing of the severely
injured muscles and severely injured nerves and brain injuries
(15-23, 59) so far not mentioned with DMDs (61), these results
obtained in two models, cysteamine enema and then colon-colon
anastomosis and cuprizone may define a particular way not
relied on immunomodulation.
Analyzing this study with same dosage regimen used, and
the same per-oral protocol, this shows BPC 157's potential to
counteract the consequences of the cuprizone application even
an extremely high regimen that highly exceeds those commonly
applied (62, 65). In general, this BPC 157's protocol accords
with all protocols used before in studies evidencing BPC 157's
healing of the severely injured muscles and severely injured
nerves and brain injuries (15-23, 59).
Likewise, along with previous beneficial effect of BPC 157
in gastrointestinal tract, and inflammatory bowel disease
complications that were accordingly solved (10, 11), poor
healing of the fistulas (35), unhealed intestinal anastomosis (42,
43), massive intestinal resection leading to short bowel (43)) this
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Fig. 7. Illustrative course after induction of ulcerative colitis (cysteamine enema) and colon-colon anastomosis in controls, not presented
in cysteamine enema + colon-colon anastomosis + BPC 157 rats. Controls (C, right, small italics) (saline 5 ml/kg intraperitoneally or only
drinking water 12 ml/day) presented with very poor anastomosis healing, i.e., day 7, necrosis and dehiscience (a), along with prominent
ulcerative colitis, present below and up anastomosis (b); and day 3 (HE (upper), Mallory (middle) staining, ×40): wide gap (c), great
amount of inflammatory cells, collagen (green fibers, Mallory staining) only in mucosa and submucosa (d); day 7: subileus with adhesions
(e). Animals that received BPC 157 (B, left, capitals) (10 µg/kg, 10 ng/kg) either intraperitoneally once a day (first application
immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 µg/ml/12 ml/day till the sacrifice),
demonstrated significantly improved healing, i.e., day 7; advanced anastomosis healing (A), macoscopicallly preserved mucosa (B), day
3 (HE (upper), Mallory (middle) staining, ×40): smaller gap (C), less inflammatory cells, collagen in mucosa and submucosa and
granulation tissue (green fibers, Mallory staining) (D); day 7: functionally (no ileus), presentation was similar to healthy animals (E).
study shows BPC 157's high potential to heal colon-colon
anastomosis along with cysteamine colitis, thus, potential to
counteract the consequences of the anastomosis for cysteamine
colitis, and vice versa, convalescing the increased healing failure
of anastomosis healing due to concomitant presentation of
severe colitis. Thus, providing the suitability of the both models,
and damaging regimens used, these arguments (i.e., chosen
cuprizone administrations multiply beyond those cuprizone
regimens commonly used and this should ascertain the value of
the obtained counteracting effect; accordingly with
inflammatory bowel disease, cysteamine damaging effect
particularly includes both upper and lower GI tract lesions (5-7,
9) may evidence BPC 157 effectiveness as a comparative link in
both diseases.
Specifically, the addition of cuprizone (bis-cyclohexanone
oxalydihydrazone), to the diet process (66) produces a massive
demyelination in different areas of the CNS and particularly in
the corpus callosum (67-69). Demyelination is closely followed
by recruitment of microglia and by phagocytosis of the disrupted
myelin membrane. If the administration of cuprizone is
terminated, an almost complete remyelination takes place in a
matter of weeks (68, 70, 71). Here, using a several times higher
cuprizone diet, followed by concomitant additional intragastrical
administrations of huge cuprizone quantity, we clearly
exaggerate and speed up the damaging process; and accordingly
nerve damage appeared in various brain areas, with most
prominent damage in corpus callosum, laterodorsal thalamus,
nucleus reunions, anterior horn motor neurons, regional
heterogeneities which suggest differences in the underlying
pathophysiology as it had been previously claimed (72).
Thereby, it is important to indicate that with consistently less
nerve damage in all damaged areas in all BPC 157-cuprizone
rats, the most important evidence is the consistent beneficial
effect of BPC 157 also in those areas that were most affected,
and thereby markedly improved gross presentation and functions
in BPC 157 rats. Consistently, BPC 157 counteracted cerebellar
ataxia (63), and impaired forelimb function (64), thus, it
recovers both proximal and distal forelimb function including
digit movements during a naturally occurring behavior that does
not require extensive training or deprivation to enhance
motivation (64). Even more intriguing is the presentation of right
forelimb sparing and disability (reacting with only left or no
forelimb upon challenge with forceps have difficulty with
maintaining body balance while rearing), common in cuprizone
rats, not presented in BPC 157-cuprizone rats (normal
functioning of right forelimb, simultaneous reaction with both
forelimbs, and grasp the forceps, and maintain body balance
while rearing as healthy rats). Like in previous studies, BPC 157
consistently attenuates all encephalopathies that affect various
brain areas, and that were induced by different agents, given in
huge over-dose, such as paracetamol, diclofenac, ibuprofen or
insulin. It also counteracts corresponding behavioral
disturbances i.e., prolonged sedation (diclofenac (22), ibuprofen
(21)), seizures (insulin (23), paracetamol (20)). Likewise, a
consistent beneficial effect of BPC 157 was evidenced in mice
after traumatic brain injury (19). In accordance with the primary
injury to the brain that initiates a secondary injury process of
traumatic brain injury, the BPC 157 counteracting effects
concerned the immediate consequences of severe head injury in
mice, the preserved consciousness (with less unconsciousness
and fatality). Also, BPC 157 attenuated and improved the
postponed deleterious outcome (lower brain edema, significantly
lower number and size of haemorrhagic traumatic lacerations,
significantly lower intensity of subarachnoidal bleeding,
significantly less intraventricular haemorrhage shown
microscopically, declined fatality) (19).
Besides, considering the cuprizone effect on schizophrenia
and thereby antipsyhotics in cuprizone model (73) BPC 157 also
counteracts amphetamine toxicity, both acute and chronic (74,
75), like MPTP-toxicity and lethality (76), as well as catalepsy
that may be produced by various neuroleptics (77). In addition,
considering the serotonin system (i.e., fluoxetine (78) sertraline
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Fig. 8. Presentation of right forelimb sparing and
disability in cuprisone (control, small letters, left),
not presented in cuprisone + BPC 157 rats
(capitals, right). Control, left, rat not using right
forelimb (a), reacting with only left (b) forelimb (or
no forelimb) upon challenge with forceps, having
difficulty with maintaining body balance (c),
common presentation in cuprizone control rats.
BPC 157, right, normal functioning of right
forelimb (A), simultaneous reaction with both
forelimbs (B), and grasp the forceps (A, B), and
maintaining body balance as healthy rats (C),
common presentation in cuprizone + BPC 157 rats.
(79), promote remission in acute experimental autoimmune
encephalomyelitis) BPC 157 affects with region specific
influence the brain serotonin synthesis (a-[14C]methyl-l-
tryptophan autoradiographic measurements) (80), reduces the
duration of immobility to a greater extent than imipramine (81).
Also, given peripherally, BPC 157 counteracts serotonin-
syndrome, and has a particular increase in serotonin in substantia
nigra, acutely and chronically (80).
Thus, it seems that these findings provide convincing
evidence that BPC 157 may be also useful in cuprizone-rats. In
addition, BPC 157 exhibits a particular effect on muscle healing
in general terms as well. Of note, the extent of the demonstrated
beneficial effect on recovery of muscle function and integrity is
considerable, and involves the transection- (15, 37) crush- (16,
17) lesion of striated muscle, and healing impairment induced by
systemic corticosteroid application (16), as well as function
impairment induced by centrally acting agents (74, 75). Finally,
BPC 157 markedly improves the healing of traumatic nerve (18)
and traumatic brain injury (19) and ameliorates encephalopathies
that occur in severely intoxicated animals (20-23) and therefore,
exhibits particular neuroprotective ability. Besides, the BPC 157
healing involves also the smooth muscle functions, formations of
new smooth muscle stands at the site of injury (5), prominent
adaptation after resection injury (43) and rescuing of the failed
sphincter function (82-85). Therefore, seen from the viewpoint of
the inflammatory bowel disease-multiple sclerosis connections
throughout BPC 157, the final proof should be the corresponding
effectiveness in both models, multiple sclerosis as well as
ulcerative colitis. Thus, the BPC 157's extension to inflammatory
bowel disease (or from inflammatory bowel disease) seems to be
well backed presented with favorable both animal data in various
models of intestinal damages, and clinical data in inflammatory
bowel patients (5-7, 9).
Summarizing, while current biological therapy which
presumably seeks to target specific immune and biochemical
abnormalities at the molecular and cellular level, the stable
gastric pentadecapeptide BPC 157 evidence is more general, and
from this point of view, even more suited for additional
applications. For instance, reversed were increased number of
inflammatory cells (38, 44-46) and the rise of leukotriene B4
(LTB4), thromboxane B2 (TXB2), and myeloperoxidase (MPO) in
the serum and inflamed tissues (47-49). BPC 157 increased
macrophages activity (44). BPC 157 counteracted deleterious
effects of NO-system blockade (i.e., BPC 157 reversed NO-
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Fig. 9. Brain lesions in rats that received cuprizone diet, and then cuprizone intragastrical applications, and thereby, cuprizone toxicity
manifestations. BPC 157 (10 µg/kg, 10 ng/kg) was applied either per-orally in drinking water (0.16 µg/ml/12 ml/day; 0.16 ng/ml/12
ml/day till the sacrifice) and intragastrically after cuprizone instilations, while controls received simultaneously drinking water only
(12 ml/day) as well as an equivolume of saline (5 ml/kg) intragastrically after cuprizone instillations. Characterisistic presentation of
parietal neocortex (PC, PB), left (control (PC), more neurons damage (black arrow indicates ballonized neuron); BPC 157, (PB), less
neurons damage (black arrow indicates ballonized neuron; white arrow indicates normal neuron) and hippokampal region CA1, right
(control (HC), more neurons damage (black arrow indicates ballonized neuron, white arrow indicates normal neuron); BPC 157 (HB),
less neurons damage (black arrow indicates ballonized neuron; white arrow indicates normal neuron). Nissl ×20.
system blockade-complete failure of fistulas healing (35), and the
same BPC 157-NO-system interaction was also seen in other
models and in various species (4, 8, 25-27)). BPC 157 stimulated
expression of egr-1 gene (but also its repressor nab2 (44)) and
this should be implemented in BPC 157's wound healing
capability (i.e., gastrointestinal tract, muscle, nerve, brain lesions
healing)) (5-7, 9), and cytokine and growth factor generation and
early extracellular matrix (collagen) formation (44). Therefore,
for BPC 157 in both inflammatory bowel disease and multiple
sclerosis, we should consider significance of both NO-system and
egr-1 gene-systems for both inflammatory bowel disease and
multiple sclerosis (54-57). Multiple sclerosis is characterized by
the progressive damage or loss of oligodendrocytes and this may
be closely related to egr-1 gene (58). Thereby, more use of
models of inflammatory bowel disease (and in particular, more
effectiveness in cysteamine colitis rats with colon-colon
anastomosis), better evidence for multiple sclerosis models
(especially, cuprizone application) would be ascertained. Thus,
various intestinal lesions models cured, even when complicated
with relapse; poor healing of the fistulas; intestinal anastomosis;
massive intestinal resection leading to short bowel, and
functional incapability of the post-anastomotic remained
intestine, all together indicate most improvement achieved by
BPC 157 regimens, per-orally, parenterally and locally (10, 11,
35, 42, 43). Such advanced effectiveness (macro/microscopically,
functionally, biomechanically) in healing may be perceived as an
additional proof of BPC 157/inflammatory bowel
disease/multiple sclerosis concept.
Especially, considering the anastomosis as a particular
intestinal wound that needs all processes to be accommodated
before the healing of the anastomosis could occur (5-7, 9, 42, 43),
the suggested particular effect on endothelium integrity, termed
also "wound healing therapy", clearly covers the cysteamine colitis
healing in the same way (5-7, 9). This generalization may explain
initial particular extensions from inflammatory bowel research,
throughout a short term period and long term therapy, toward the
disturbances, such as multiple sclerosis search as well (5-7, 9).
Clearly, huge stability, i.e., stable in human gastric juice
more than 24 hours, and use without carrier (otherwise, peptide
+ carrier(s) -complex bears considerable methodological/activity
dilemmas), prominent antiulcer effect, and a safe application in
inflammatory bowel disease patients with improved
wound/intestinal anastomosis healing, adhesion prevention,
collagen deposition, and anastomotic strength, along with
prominent effect in cuprizone rats (i.e., particularly intoxicated
with much higher diet and additional intragastrical applications)
(5-7, 9) as well as in other encephalopathies (20-23) and brain
damage (19) and muscle (15-17) and nerve (18) disorders, all
together support the special pentadecapeptide characteristics and
practical importance. Thereby, we advocate the stable gastric
pentadecapeptide BPC 157 in both inflammatory bowel disease
and multiple sclerosis therapy.
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